Latest in News & Research
Nevi, Genetic Predisposition More Strongly Linked to Second Melanoma
Association stronger with second versus first primary melanoma for having many moles at age 21 years, high genetic predisposition
Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer
More than twofold increased risk of prostate cancer seen for men with first melanoma diagnosed 10 to 15 years before study recruitment
QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
Quality of life favored the pembrolizumab arm versus standard-of-care arm receiving ipilimumab, high-dose interferon α 2b
Early Application of Emollients Prevents Development of Eczema
Of the types of emollient, emulsion was suggested as the better option for preventing infant atopic dermatitis development
Can a Machine Learning Tool Be Used to Improve Psoriasis Patient Outcomes?
Machine learning-based tool that predicts response to biologics significantly altered physician prescribing and improved patient outcomes
Can Risk for Skin Cancer Be Predicted in Solid Organ Transplant Recipients?
SUNTRAC risk assessment calculator predicted incidence of skin cancer with predicted and observed incidence of 6.2 and 7.0 percent, respectively
Isolated Nail Psoriasis Does Not Increase Risk for Metabolic Syndrome
Both metabolic syndrome components and related medical conditions seen at similar rates between patients with, without isolated nail psoriasis
Vitamin D Supplements Do Not Reduce Asthma Exacerbations Overall
Supplements reduce risk among children with low serum 25(OH)D and have beneficial effects in children with atopic dermatitis, allergic rhinitis
Thermal Images Differentiate Healed From Unhealed Wounds
Thermal images taken in home settings at week 0 can discriminate healed from unhealed leg venous ulcer wounds
Do Clinical Characteristics of Rosacea in Women Differ With Age?
Patients aged 45 years or older at diagnosis more likely to have serious persistent erythema and telangiectasia
How Do Lip Filler Products Differ in Terms of Outcomes?
No one product is superior for all categories; more of an increase seen in lip heig
Diversity Gaps Persist in Dermatology Workforce Pipeline
Students pursuing dermatology have lower odds of intending to care for underserved populations, practice in underserved areas
Update Shows Relatlimab Nivolumab Slows Advanced Melanoma
Progression-free survival prolonged with relatlimab nivolumab versus nivolumab alone for previously untreated advanced melanoma
Urban Dwelling Indigenous Young People Face Higher Burden of Skin Conditions
Incidence rates of atopic dermatitis and bacterial skin infections higher among urban-living Indigenous children and young people in high-income countries
Are Hyaluronic Acid Fillers With Mepivacaine, Lidocaine Equally Effective?
Mepivacaine found to be noninferior versus lidocaine for pain relief and bilateral wrinkle improvement
Can Vitamin D Supplementation Cut Incidence of Keratinocyte Cancer?
Researchers find no evidence that vitamin D supplementation reduces incidence of keratinocyte cancer
Subset of Stage I Melanoma Patients ID'd With Very Low Mortality
Younger age at diagnosis, Clark level II linked to low risk for death among patients with stage I lesions, negative clinical nodes
Monkeypox Infection Rare in Children, Adolescents Younger Than 18
Monkeypox virus infection among <18s accounted for 0.3 percent of reported cases; most children were not hospitalized
Presymptomatic Transmission Seen With Monkeypox
Transmission detected up to a maximum of four days before onset of symptoms
Improvements Sustained With Continuing Apremilast in Psoriasis
Static Physician's Global Assessment response maintained for those continuing apremilast, receiving apremilast after placebo
Serum Dupilumab Levels Not Linked to Treatment Response in Eczema
Odds ratios for serum dupilumab levels at 16 weeks predicting long-term response and adverse events not significant
Psoriasis Not Tied to Myocardial Infarction in Patients With ESRD
Confounding variables, particularly comorbidities, impact association
Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent
24 of 1274